1. Medicare, Medicaid and CLIA Programs: Regulations Implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Final rule. Fed. Regi. 57:7002, 1992. Available at http://www.fda.gov/ cdrh/clia.
2. Medicare, Medicaid and CLIA Programs; Laboratory Requirements Relating to Quality Systems and Certain Personnel Qualifications; Final Rule (January 24, 2003) Fed. Regi. 68:3640, 2003.
3. American College of Medical Genetics (ACMG). Standards and Guidelines for Clinical Genetics Laboratories. 3rd ed. Avalable at http://www.acmg.net.
4. College of American Pathology. Molecular pathology checklist. Avalable at http://www.cap.org.
5. NCCLS. Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline. NCCLS document MM1-A. NCCLS, Wayne, PA, 2000.
6. McGovern, M., Benach, M., Wallenstein, S., Desnick, R., and Keenlyside, R. Quality assurance in molecular genetic testing laboratories. JAMA 281:835-840, 1999.
7. Hofgartner, W. T. and Tait, J. F. Characteristics of clinical molecular-genetic testing laboratories in the United States. Clin. Chem. 45(8): 1288-1290, 1999.
8. Van Deerlin,V. Personal communication, 2003.
9. Beutler, E., Gelbart ,T., and Kuhl, W. Interference of heparin with the polymerase chain reaction. BioTechniques. 9:166, 1990.
10. Ginocchio, C. C., Wang, X. P., Kaplan, M. H., et al. Effects of specimen collection, processing and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J. Clin. Microbiol. 11:2886-2893, 1997.
11. Farkas, D. H., Drevon, A. M., Kiechle, F. L., DiCarlo, R. G., Heath, E. M., Crisan, D. Specimen stability for DNA-based diagnostic testing. Diagn. Mol. Pathol. 5(4): 227-235, 1996.
12. Dicover, R. E., Herman, S. A., Saddiqu, K., Wafer, D., Dillon, M., and Bryson, Y. J. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J. Clin. Microbiol. 36: 1070-1073, 1998.
13. New York State Department of Health Laboratory, Wadsworth Center. Clinical Laboratory Evaluation Program, Laboratory Standards. Available at http://www.wadsworth.org/labcert/. (accessed February 2002).
14. NCCLS. Clinical Laboratory Technical Procedure Manuals, 4th ed. Approved Guideline GP2-A4.NCCLS Wayne, PA, 2002.
15. Gentra Systems. Purigene DNA Isolation Kit, Gentra Systems, Minneapolis, MN. Available at http://www.gentra.com.
16. Kwok, S. and Higuchi, R. Avoiding false positive with PCR. Nature 339:237-238, 1989.
17. Longo, M. C., Berninger, M. S., and Hurtley, J. L. Use of uracil DNA glycosylase to control carry-over contamination in poly-merase chain reactions. Gene 93:125-128, 1990.
18. Association for Molecular Pathology Statement. Recommendations for in-house development and operation of molecular diagnostic tests. Am. J. Clin. Pathol. 111:449-463, 1999.
19. Shahangian, S., Holmes, E. H., and Taylor, R. Toward optimal PT use. Med. Lab. Observ. 32(4):32-43, 2000.
20. Schwartz, M. K. Genetic testing and the Clinical Laboratory Improvement Amendment of 1988: present and future. Clin. Chem. 45(5):739-745, 1999.
21. The Health Insurance Portability and Accountability Act of 1996 (Public Law 104-191). Standards for Privacy of Individually Identifiable Health Information-45 CFR Parts 160 and 164.
Was this article helpful?
Prior to planning pregnancy, you should learn more about the things involved in getting pregnant. It involves carrying a baby inside you for nine months, caring for a child for a number of years, and many more. Consider these things, so that you can properly assess if you are ready for pregnancy. Get all these very important tips about pregnancy that you need to know.